SkyePharma_NNP annual_JJ report_NN 2002_CD Consolidated_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD Profit_NN loss_NN attributable_JJ to_TO shareholders_NNS 1,109_CD 9,452_CD Net_JJ currency_NN translation_NN effect_NN 903_CD 28_CD Lapse_NN of_IN warrants_NNS 1,096_CD 271_CD Total_JJ recognized_VBN gains_NNS and_CC losses_NNS for_IN the_DT year_NN 3,108_CD 9,153_CD As_IN described_VBN in_IN note_NN 22a_NNS :_: Share_NNP Capital_NNP ,_, the_DT B_NNP Warrants_NNS relating_VBG to_TO the_DT acquisition_NN of_IN Krypton_NNP lapsed_VBD on_IN 31_CD December_NNP 2002_CD ._.
The_DT fair_JJ value_NN of_IN the_DT lapsed_VBN warrants_NNS of_IN 1,096,000_CD has_VBZ been_VBN transferred_VBN from_IN non-distributable_JJ reserves_NNS to_TO retained_VBN profits_NNS ._.
In_IN 2001_CD the_DT class_NN C_NNP Warrants_NNS relating_VBG to_TO the_DT debenture_NN issue_NN lapsed_VBD ._.
The_DT fair_JJ value_NN of_IN the_DT warrants_NNS at_IN issue_NN of_IN 271,000_CD was_VBD transferred_VBN from_IN non-distributable_JJ reserves_NNS to_TO retained_VBN profits_NNS ._.
The_DT lapse_NN of_IN warrants_NNS represents_VBZ a_DT transfer_NN of_IN value_NN from_IN the_DT warrant_NN holders_NNS to_TO existing_VBG shareholders_NNS ._.
In_IN accordance_NN with_IN FRS4_NNP :_: Capital_NNP instruments_NNS ,_, this_DT is_VBZ shown_VBN as_IN a_DT recognized_VBN gain_NN ,_, although_IN total_JJ shareholders_NNS funds_NNS remain_VBP unchanged_JJ ._.
Reconciliation_NNP of_IN movements_NNS in_IN shareholders_NNS funds_NNS Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001 000 000_CD Shareholders_NNS funds_NNS at_IN the_DT beginning_NN of_IN the_DT year_NN 95,145_CD 68,952_CD Total_JJ recognized_VBN gains_NNS and_CC losses_NNS for_IN the_DT year_NN 3,108_CD 9,153_CD Goodwill_NNP adjustments_NNS on_IN deferred_JJ consideration_NN 4,837_CD 148_CD Equity_NNP shares_NNS issued_VBD allocated_VBN ,_, net_NN of_IN expenses_NNS 43,816_CD 29,599_CD Exercise_NN of_IN share_NN options_NNS ,_, net_NN of_IN expenses_NNS 700_CD 459_CD Non-equity_JJ shares_NNS converted_VBD to_TO equity_NN shares_NNS 11,310_CD Decrease_NN increase_NN in_IN shares_NNS and_CC warrants_NNS to_TO be_VB issued_VBN 5,780_CD 5,780_CD Revaluation_NNP of_IN shares_NNS and_CC warrants_NNS to_TO be_VB issued_VBN 4,837_CD 148_CD Issue_NN of_IN warrants_NNS 311_CD Exercise_NN of_IN warrants_NNS 624_CD 56_CD Lapse_NN of_IN warrants_NNS 1,096_CD 436_CD Net_JJ movement_NN in_IN the_DT year_NN 29,125_CD 26,193_CD Shareholders_NNS funds_NNS at_IN the_DT end_NN of_IN the_DT year_NN 124,270_CD 95,145_CD consolidated_JJ statement_NN of_IN total_JJ 51_CD recognized_VBN gains_NNS and_CC losses_NNS reconciliation_NN of_IN movements_NNS in_IN shareholders_NNS funds_NNS
